Mostrar el registro sencillo del ítem

Otros

dc.creatorRivero-Juárez, Antonioes
dc.creatorMira, Jose A.es
dc.creatorSantos-Gil, Ignacio De Loses
dc.creatorLópez Cortés, Luis Fernandoes
dc.creatorGirón-González, José-Antonioes
dc.creatorMárquez, Manueles
dc.date.accessioned2019-02-26T13:38:55Z
dc.date.available2019-02-26T13:38:55Z
dc.date.issued2013
dc.identifier.citationRivero-Juarez, A., Mira, J.A., Santos-Gil, I.D.L., López Cortés, L.F., Girón-González, J. y Márquez, M. (2013). Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C.
dc.identifier.urihttps://hdl.handle.net/11441/83506
dc.descriptionComunicación cortaes
dc.description.abstractWe assessed the relationship between atazanavir (ATV)-based antiretroviral treatment (ART) and plasma hepatitis C virus (HCV) viral load in a population of HIV/HCV-coinfected patients. HIV/HCV-coinfected patients who received ART based on a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) were included. Patients were stratified by ART drug [ATV/rtv, lopinavir (LPV/rtv), efavirenz (EFV), nevirapine (NVP), and other PIs], HCV genotype (1/4 and 2/3), and IL28B genotype (CC and non-CC). The Kruskal-Wallis test and chi-squared test were used to compare continuous and categorical variables, respectively. Multivariate analysis consisted of a stepwise linear regression analysis. Six hundred and forty-nine HIV/HCV-coinfected patients were included. HCV genotype 1/4 patients who received ATV had higher HCV RNA levels [6.57 (5.9-6.8) log IU/ml] than those who received LPV [6.1 (5.5-6.5) log IU/ml], EFV [6.1 (5.6-6.4) log IU/ml], NVP [5.8 (5.5-5.9) log IU/ml], or other PIs [6.1 (5.7-6.4) log IU/ml] (p=0.014). This association held for the IL28B genotype (CC versus non-CC). The association was not found in patients carrying HCV genotypes 2/3. The linear regression model identified the IL28B genotype and ATV use as independent factors associated with HCV RNA levels. ATV-based therapy may be associated with a higher HCV RNA viral load in HIV/HCV-coinfected patients.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.relation.ispartofnull
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAtazanavires
dc.subjectHepatitis Ces
dc.subjectHIV Type 1es
dc.titleAtazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis Ces
dc.typeinfo:eu-repo/semantics/otheres
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.identifier.doi10.1089/aid.2012.0126es
dc.contributor.groupUniversidad de Sevilla. CTS-203: Estudio de las Enfermedades Infecciosases
idus.format.extent3es

FicherosTamañoFormatoVerDescripción
ATAZANAVIR.pdf77.30KbIcon   [PDF] Ver/Abrir   atazanavir

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional